 Phase III: The PFS for capecitabine chemotherapy alone is expected to be about 5.5 months and this is expected to increase to 9 months with the addition of bevacizumab, which is considered to be clinically meaningful. Using an overall 95 confidence level and 80 power and a 2.5 significance level for each comparison 111 patients per arm are required to detect differences based on a 36-month accrual and 12-month follow-up. 